Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 14/20 | 0.56 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TPO | P07202 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | EPX | P11678 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2573719 | 0.85 | MPO (0.44) | MPO | |
| Sampirtine SCHEMBL1230637 | 0.80 | MPO (0.49) | MPOADCY10 | |
| Sampirtine SCHEMBL29973209 | 0.80 | MPO (0.49) | MPOADCY10 | |
| SCHEMBL9537122 | 0.80 | DHFR (0.43) | MPOADCY10 | |
| SCHEMBL18585821 | 0.79 | MPO (0.65) | MPOADCY10TPOCYP3A4 | |
| Sampirtine SCHEMBL10569152 | 0.79 | MPO (0.48) | MPOADCY10 | |
| SCHEMBL28960523 | 0.77 | MPO (0.45) | MPOADCY10MAPTCYP3A4 | |
| SCHEMBL18618865 | 0.77 | MPO (0.58) | MPOTPOCYP3A4EPX | |
| SCHEMBL3906522 | 0.74 | MPO (0.43) | MPOADCY10MAPT | |
| SCHEMBL18620324 | 0.73 | MPO (0.53) | MPOADCY10MAPTTPOCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10494404-B2 | Quinolinium conjugates of cyclosporin | UCL BUSINESS PLC (GB) | 2019-12-03 | — | — | US | disclosed |
| US-20170349632-A1 | QUINOLIUM CONJUGATES OF CYCLOSPORIN | UCL BUSINESS PLC (GB) | 2017-12-07 | — | — | US | disclosed |
| US-20120122892-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-8129403-B2 | e.g. 2-[9-(5-Cyclopropyl-1H-pyrazol-3-yl)-6-methyl-9H-purin-2-ylamino]-2-(4-fluorophenyl)ethanol; tropomyosin-related kinases (Trk's) inhibitor; anticarcinoganic agent; solid tumors and leukemia | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-7622482-B2 | anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine | ASTRAZENECA (SE) | 2009-11-24 | — | — | US | disclosed |
| US-20090137624-A1 | anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| US-20080176872-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176872-A1 | Chemical Compounds | TP53, XPOT, KRAS | MPO 2249/4885ADCY10 1730/4885MAPT 1211/4885 |
| US-10494404-B2 | Quinolinium conjugates of cyclosporin | SQOR, SHMT2, CS | MPO 1016/4885ADCY10 2307/4885MAPT 1989/4885 |
| US-20170349632-A1 | QUINOLIUM CONJUGATES OF CYCLOSPORIN | SHMT2, CS, SQOR | MPO 1332/4885ADCY10 2075/4885MAPT 2112/4885 |
| US-20120122892-A1 | CHEMICAL COMPOUNDS | TP53, XPOT, KRAS | MPO 2035/4885ADCY10 1950/4885MAPT 1265/4885 |
| US-20090137624-A1 | anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine | ERBB4, ERBB2, ABL1 | MPO 3431/4885ADCY10 3966/4885MAPT 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.